{"id":603265,"date":"2026-09-02T03:57:15","date_gmt":"2026-09-02T03:57:15","guid":{"rendered":"https:\/\/www.newsbeep.com\/il\/603265\/"},"modified":"2026-09-02T03:57:15","modified_gmt":"2026-09-02T03:57:15","slug":"braveheart-bio-to-participate-in-cantor-global-healthcare-conference","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/il\/603265\/","title":{"rendered":"Braveheart Bio to Participate in Cantor Global Healthcare Conference"},"content":{"rendered":"

SAN FRANCISCO, Sept. 01, 2026 (GLOBE NEWSWIRE) — Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases, today announced that it will participate in the Cantor Global Healthcare Conference, being held September 9-11 in New York, NY. Management will participate in a fireside chat on Thursday, September 10, 2026 at 3:20 p.m. EDT.<\/p>\n

Interested parties may access a live webcast by visiting the News & Events section of the Braveheart website at https:\/\/ir.braveheart.bio\/<\/a>, with replays available in a temporary archive following the event.<\/p>\n

About Braveheart Bio <\/p>\n

Braveheart Bio is a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. Braveheart Bio\u2019s lead product candidate, BHB-1893, is a next-generation oral small-molecule cardiac myosin inhibitor (CMI) being developed for the treatment of obstructive HCM (oHCM) and non-obstructive HCM (nHCM). Braveheart Bio is aiming to address the limitations of currently available CMIs by designing BHB-1893 for rapid onset, consistent depth of response, preservation of systolic function, prompt reversibility, and a straightforward approach to titration and monitoring.<\/p>\n

Investor Relations Contact
Alexander Sharif
New Street Investor Relations
Alexander@NewStreetIR.com<\/a>\n\t\t<\/p>\n

Media Contact
FGS Global
Braveheart-bio@fgsglobal.com<\/a> \u00a0<\/p>\n

\"Primary<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"SAN FRANCISCO, Sept. 01, 2026 (GLOBE NEWSWIRE) — Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing…\n","protected":false},"author":2,"featured_media":603266,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10],"tags":[163,85,46],"class_list":["post-603265","post","type-post","status-publish","format-standard","has-post-thumbnail","category-health","tag-health","tag-il","tag-israel"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts\/603265","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/comments?post=603265"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts\/603265\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/media\/603266"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/media?parent=603265"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/categories?post=603265"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/tags?post=603265"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}